TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
"TCR2 continued to execute on its streamlined corporate priorities in the last quarter and stands poised to deliver multiple clinical catalysts over the next 12 months on our two core assets, gavo-cel and TC-510," said
- TCR2 announced positive topline results from the complete Phase 1 dose escalation portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors. Twenty-eight of the 30 patients evaluable for efficacy experienced regression of their target lesions, including eight patients who achieved a partial response (PR) by target lesion assessment, six of whom met criteria for a PR according to RECIST 1.1 criteria. Following identification of a dose-limiting toxicity (DLT) in
September 2021, the study proceeded to a dose de-escalation portion and subsequently declared dose level 3 (1x108 cells/m2 following lymphodepletion) the recommended Phase 2 dose (RP2D).
- Enrollment and treatment in the Phase 2 expansion portion of the gavo-cel Phase 1/2 clinical trial is ongoing.
- TCR2 presented new preclinical data at
The Society for Immunotherapyof Cancer’s (SITC) 37th Annual Meeting demonstrating gavo-cel maintained effector function to clear tumors and was not impaired, blocked or disrupted by functional suppression from supraphysiological levels of soluble mesothelin-related peptides.
• Enrollment and treatment in the Phase 1 dose escalation portion of the TC-510 Phase 1/2 clinical trial is ongoing.
- Cash Position: TCR2 ended the third quarter of 2022 with
$176.0 millionin cash, cash equivalents, and investments compared to $265.6 millionas of December 31, 2021. Net cash used in operations was $25.8 millionfor the third quarter of 2022 compared to $19.4 millionfor the third quarter of 2021. TCR2 continues to project net cash use of $115-125 millionfor 2022. We expect cash on hand to support operations into 2024.
- R&D Expenses: Research and development expenses were
$24.8 millionfor the third quarter of 2022 compared to $20.3 millionfor the third quarter of 2021. The increase in R&D expenses was primarily due to an increase in clinical trial expenses associated with patient treatment and product manufacturing.
- G&A Expenses: General and administrative expenses were
$6.3 millionfor the third quarter of 2022 compared to $6.0 millionfor the third quarter of 2021. The slight increase in general and administrative expenses was due to an increase supporting corporate activities.
- Net Loss: Net loss was
$30.6 millionfor the third quarter of 2022 compared to $26.2 millionfor the third quarter of 2021.
TCR2 Therapeutics management is scheduled to participate at the following upcoming conferences.
Jefferies London Healthcare Conference: Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress on Tuesday, November 15, 2022at 5:35pm GMT( 12:35pm ET)
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit www.tcr2.com.
Gavo-cel is a mesothelin-targeted TRuC-T cell. The ongoing gavo-cel Phase 1/2 clinical trial is evaluating the safety and efficacy of gavo-cel in patients with mesothelin-expressing malignant pleural/peritoneal mesothelioma (MPM), ovarian cancer, non-small cell lung cancer (NSCLC) and cholangiocarcinoma.
TC-510 is a mesothelin-targeted TRuC-T cell that co-expresses a PD-1:CD28 chimeric switch receptor to provide a local costimulatory signal by engaging with PD-L1 expressed in the hostile tumor microenvironment and converting the negative inhibitory signal into a positive costimulatory signal.
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. The use of words such as "will," "expects," "plans," "believes," "predicts," "projects," "aims," "allows," “promising,” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding TCR2’s plans, strategies, timelines, and expectations for its gavo-cel and TC-510 clinical trials, statements regarding IND-enabling studies on TC-520, express or implied statements regarding the therapeutic potential of gavo-cel, TC-510 and TCR2’s other product candidates in treating cancer patients and improving access to investigational therapies for cancer, and statements regarding expected cash use in 2022 and cash runway into 2024.
The expressed or implied forward-looking statements included in this press release are only current expectations, beliefs, and predictions and are subject to a number of risks, uncertainties, assumptions and important factors, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure manufacturing capacity; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the
Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor and Media Contact:
Senior Director, Investor Relations and Corporate Communications
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share data)
|Cash and cash equivalents||$||54,006||$||222,564|
|Prepaid expenses and other current assets||8,093||10,534|
|Total current assets||184,079||276,127|
|Property and equipment, net||29,083||17,075|
|Right-of-use assets, operating leases||57,704||28,283|
|Other assets, non-current||909||730|
|Liabilities and stockholders’ equity|
|Accrued expenses and other current liabilities||13,185||13,094|
|Operating lease liabilities||20,545||3,367|
|Total current liabilities||36,693||18,605|
|Operating lease liabilities, non-current||37,684||22,996|
|Additional paid-in capital||639,981||631,008|
|Accumulated other comprehensive income (loss)||(596||)||(13||)|
|Total stockholders’ equity||198,550||281,477|
|Total liabilities and stockholders’ equity||$||272,927||$||323,371|
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
|Three Months Ended
||Nine Months Ended
|Research and development||$||24,791||$||20,277||$||73,441||$||54,828|
|General and administrative||6,312||5,963||18,636||17,297|
|Total operating expenses||31,103||26,240||92,077||72,125|
|Loss from operations||(31,103||)||(26,240||)||(92,077||)||(72,125||)|
|Interest income, net||510||38||925||186|
|Loss before income tax expense||(30,593||)||(26,202||)||(91,152||)||(71,939||)|
|Income tax expense||1||42||165||129|
|Per share information|
|Net loss per share of common stock, basic and diluted||$||(0.79||)||$||(0.69||)||$||(2.37||)||$||(1.91||)|
|Weighted average shares outstanding, basic and diluted||38,620,751||38,197,929||38,567,331||37,816,345|
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
|Nine Months Ended
|Adjustments to reconcile net loss to cash used in operating activities:|
|Depreciation and amortization||2,300||1,976|
|Stock-based compensation expense||8,717||9,525|
|(Accretion) / Amortization on investments||(403||)||626|
|Deferred tax liabilities||(293||)||105|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||2,618||(41||)|
|Operating leases, net||2,445||(2,811||)|
|Accrued expenses and other liabilities||66||2,299|
|Cash used in operating activities||(76,504||)||(58,323||)|
|Purchases of equipment||(12,681||)||(4,352||)|
|Software development costs||(330||)||(308||)|
|Purchases of investments||(215,619||)||(40,732||)|
|Proceeds from sale or maturity of investments||136,488||140,622|
|Cash provided by (used in) investing activities||(92,142||)||95,230|
|Proceeds from public offering of common stock, net of issuance costs||-||131,330|
|Proceeds from the exercise of stock options||256||1,013|
|Payment of deferred offering costs||(172||)||(336||)|
|Cash provided by financing activities||84||132,007|
|Net change in cash, cash equivalents, and restricted cash||(168,562||)||168,914|
|Cash, cash equivalents, and restricted cash at beginning of year||223,720||94,738|
|Cash, cash equivalents, and restricted cash at end of period||$||55,158||$||263,652|
Source: TCR2 Therapeutics